The different major find more therapy options used are: 33% first line patients were treated with dacarbazine, 20% with fotemustine, and 12% with a combination of dacarbazine+fotemustine; in second line, 51% of patients were treated with fotemustine, and 10% with dacarbazine; in third line, fotemustine was used for 40% of patients, while dacarbazine for 8% of patients. The mean age at the diagnosis was 55 years and male patients represented 62.9% of the sample. Among the 300 therapeutic treatments 42.8% showed some response to systemic therapy. Within each
line of therapy – that is net of double counting – response rate was lower (36.1% in the first line, 30.4% see more in the second line and 34.1 in the third line). The total length of follow-up time was 17.5 months, with lower durations in the first line (9.9 months) in the second line (8.9 months) and in the third line
(4.9 months). Hospitalization Hospitalizations were MM-102 not particularly frequent, with less than 10% of all patients experiencing it. Hospitalization tended to be more frequent (12.4% vs 5.9%) for patients with any response to systemic therapy in comparison with those with no response (Table 3, Table 4 and Table 5). Hospitalization was the most expensive category of resource utilisation, both among those who experienced
hospitalization (mean total cost of € 25,540) and with reference to the generality of the sample (i.e. including Dichloromethane dehalogenase patients with zero utilisation): € 2,481. Moreover, the mean cost per patient with any response to systemic therapy was higher than the mean cost per patient with no response (€ 4,524 vs € 882); the mean cost per patient in the first line of therapy (€ 2,634) was higher than the overall cost (€ 2,481), and much higher than the mean cost per patient in the second (€ 588) and third (€1.356) line of therapy. Table 3 Summary statistics for hospitalizations for patients receiving systemic therapy and/or supportive care Overall First-line therapy Second-line therapy Third-line therapy Supportive care N 215 147 112 41 24 Patients with any hospitalization N 21 11 7 4 4 % 9,8% 7,5% 6,3% 9,8% 16,7% Total length of hospitalization (days) Mean 34,3 47,5 12,7 18,8 8,2 95%CI 0-73,7 0-126,6 6,6-18,8 0-38,9 1,1-15,4 Length of hospitalization (days/month(1)) Mean 1,9 11,6 6,1 7,5 19,8 95%CI 0,6-3,2 0-30,8 0-15,3 0-27,4 0-74,2 Total hospitalization cost per hospitalized patient (€ 2009) Mean 25.400 35.200 9.400 13.900 6.100 95% CI 0-54.500 0-93.